MARKET

IDYA

IDYA

Ideaya Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.79
+0.39
+4.15%
Closed 16:00 05/29 EDT
OPEN
9.50
PREV CLOSE
9.40
HIGH
9.80
LOW
8.40
VOLUME
70.53K
TURNOVER
--
52 WEEK HIGH
12.63
52 WEEK LOW
2.950
MARKET CAP
199.73M
P/E (TTM)
-4.4587
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IDYA stock price target is 17.00 with a high estimate of 27.00 and a low estimate of 12.00.

EPS

IDYA News

More
65 Biggest Movers From Yesterday
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares climbed 386.3% to close at $19.21 on Thursday after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 1d ago
3 Strong Buy Healthcare Stocks That Could Double in the Next Year
TipRanks · 6d ago
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that Yujiro S. Hata, Chief Execut
PR Newswire · 05/19 10:00
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
PR Newswire · 05/15 11:00
IDEAYA Biosciences Highlights Publication Of Abstracts For American Association for Cancer Research Jun. 22-24
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Benzinga · 05/15 10:01
IDEAYA Biosciences Q1 EPS $(0.590) Up From $(8.690) YoY
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.590) per share. This is a 93.21 percent increase over losses of $(8.690) per share from the same period last year.
Benzinga · 05/12 10:07
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced fi
PR Newswire · 05/12 10:00
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
PR Newswire · 04/21 11:00

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About IDYA

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and WRN, in high microsatellite instability tumors (MSI) tumors.
More

Webull offers kinds of Ideaya Biosciences Inc stock information, including NASDAQ:IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions.